Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177901 | 0.93 | MEN1 (0.50) | DRD4HTR1ADRD3DRD2ITGA4 | |
| SCHEMBL6176842 | 0.91 | DRD4 (0.63) | DRD4HTR1ADRD3DRD2ITGA4 | |
| SCHEMBL6181828 | 0.84 | MEN1 (0.45) | DRD4HTR1ADRD2MEN1KMT2A | |
| Cyclohexane SCHEMBL6179896 | 0.81 | MEN1 (0.57) | DRD4HTR1ADRD2MEN1KMT2A | |
| SCHEMBL6180433 | 0.81 | MEN1 (0.53) | DRD4DRD2MEN1KMT2AOPRM1 | |
| Cyclohexane SCHEMBL6181887 | 0.80 | MEN1 (0.50) | DRD4DRD2MEN1KMT2AATM | |
| SCHEMBL6178285 | 0.79 | MEN1 (0.55) | DRD4HTR1ADRD2MEN1KMT2A | |
| SCHEMBL6179800 | 0.78 | MEN1 (0.53) | DRD4HTR1ADRD2MEN1KMT2A | |
| SCHEMBL6176194 | 0.77 | MEN1 (0.52) | DRD4HTR1ADRD2MEN1KMT2A | |
| SCHEMBL6180428 | 0.77 | MEN1 (0.50) | DRD4DRD2MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035263-A1 | Novel arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-21 | — | — | US | claimed |
| US-6326381-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | AMERICAN HOME PRODUCTS CORPORATION | 2001-12-04 | — | — | US | claimed |
| EP-1140830-B1 | ARYLPIPERIDINE AND ARYL-1,2,5,6-TETRAHYDROPYRIDINE AMIDE DERIVATIVES HAVING 5HT1A RECEPTOR ACTIVITY | WYETH CORP (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20020035263-A1 | Novel arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-21 | — | — | US | disclosed |
| US-6326381-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | AMERICAN HOME PRODUCTS CORPORATION | 2001-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035263-A1 | Novel arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives | ADRA1D, ADH1C, HTR1D | DRD4 7/4885HTR1A 11/4885DRD3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.